Title  | Date  | Price |
|---|
Javelin Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Danaher Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Medtronic Inc
Premium Company Profile
| Apr 2008 |
£265 |
Smith & Nephew plc
Premium Company Profile
| Apr 2008 |
£265 |
Transition Therapeutics Inc
Premium Company Profile
| Apr 2008 |
£265 |
TorreyPines Therapeutics Inc
Premium Company Profile
| Apr 2008 |
£265 |
St. Jude Medical Inc
Premium Company Profile
| Apr 2008 |
£265 |
Novacea Inc
Premium Company Profile
| Apr 2008 |
£265 |
Illumina Inc
Premium Company Profile
| Apr 2008 |
£265 |
Micromet Inc
Premium Company Profile
| Apr 2008 |
£265 |
C.R. Bard Inc
Premium Company Profile
| Apr 2008 |
£265 |
Avigen Inc
Premium Company Profile
| Apr 2008 |
£265 |
Optimer Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Spectrum Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Nuvelo Inc
Premium Company Profile
| Apr 2008 |
£265 |
Incyte Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Stryker Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Panacos Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
La Jolla Pharmaceutical Co
Premium Company Profile
| Apr 2008 |
£265 |
Lexicon Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Kv Pharmaceutical Company
Premium Company Profile
| Apr 2008 |
£265 |
Csl Limited
Premium Company Profile
| Apr 2008 |
£265 |
Cytori Therapeutics Inc
Premium Company Profile
| Apr 2008 |
£265 |
Carl Zeiss Meditec Ag
Premium Company Profile
| Apr 2008 |
£265 |
Boston Scientific Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Anesiva Inc
Premium Company Profile
| Apr 2008 |
£265 |
Bioms Medical Corp
Premium Company Profile
| Apr 2008 |
£265 |
Beckman Coulter Inc
Premium Company Profile
| Apr 2008 |
£265 |
Antisoma plc
Premium Company Profile
| Apr 2008 |
£265 |
Allos Therapeutics Inc
Premium Company Profile
| Apr 2008 |
£265 |
LifeCell Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Varian Medical Systems Inc
Premium Company Profile
| Apr 2008 |
£265 |
Zimmer Holdings Inc
Premium Company Profile
| Apr 2008 |
£265 |
Cougar Biotechnology Inc
Premium Company Profile
| Apr 2008 |
£265 |
MorphoSys Ag
Premium Company Profile
| Apr 2008 |
£265 |
Lev Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Introgen Therapeutics Inc
Premium Company Profile
| Apr 2008 |
£265 |
Theratechnologies Inc
Premium Company Profile
| Apr 2008 |
£265 |
Poniard Pharmaceuticals Inc
Premium Company Profile
| Apr 2008 |
£265 |
Becton, Dickinson and Co
Premium Company Profile
| Apr 2008 |
£265 |
MannKind Corporation
Premium Company Profile
| Apr 2008 |
£265 |
Cadinal Health Medical Device Company Intelligence Report
| Apr 2008 |
£395 |
Hill-Rom Medical Device Company Intelligence Report
| Apr 2008 |
£395 |
Cytogen Corporation
SWOT Analysis
| Apr 2008 |
£63 |
Collagenex Pharmaceuticals, Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Santarus, Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Nastech Pharmaceutical Company Inc
SWOT Analysis
| Apr 2008 |
£63 |
Ista Pharmaceuticals, Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Cardinal Health, Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Endo Pharmaceuticals Holdings Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Biogen Idec, Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Pfizer Inc
SWOT Analysis
| Apr 2008 |
£63 |
Amgen Inc.
SWOT Analysis
| Apr 2008 |
£63 |
Shire Plc
SWOT Analysis
| Apr 2008 |
£63 |
Merck & Co., Inc.
SWOT Analysis
| Apr 2008 |
£63 |
International Directory of Pharmaceutical Companies 2008
| Apr 2008 |
£500 |
Medtronic Medical Device Company Intelligence Report
| Mar 2008 |
£495 |
Maxygen, Inc. - SWOT Analysis
| Mar 2008 |
£63 |
Elan Corporation, plc - SWOT Analysis
| Mar 2008 |
£63 |
AstraZeneca PLC - SWOT Analysis
| Mar 2008 |
£63 |
AmerisourceBergen Corporation - SWOT Analysis
| Mar 2008 |
£63 |
Bristol-Myers Squibb Company - SWOT Analysis
| Mar 2008 |
£63 |
Merck & Co., Inc. - SWOT Analysis
| Mar 2008 |
£63 |
Sanofi-Aventis - SWOT Analysis
| Mar 2008 |
£63 |
Schering-Plough Corporation - SWOT Analysis
| Mar 2008 |
£63 |
Eli Lilly and Company - SWOT Analysis
| Mar 2008 |
£63 |
Endo Pharmaceuticals Holdings Inc. - SWOT Analysis
| Mar 2008 |
£63 |
Novartis AG - SWOT Analysis
| Mar 2008 |
£63 |
Commercial Metals Company - SWOT Analysis
| Mar 2008 |
£63 |
Auxilium Pharmaceuticals Inc - SWOT Analysis
| Mar 2008 |
£63 |
Abbott Laboratories - SWOT Analysis
| Mar 2008 |
£63 |
Amylin Pharmaceuticals Inc - SWOT Analysis
| Mar 2008 |
£63 |
Progenics Pharmaceuticals Inc - SWOT Analysis
| Mar 2008 |
£63 |
Pfizer Inc - SWOT Analysis
| Mar 2008 |
£63 |
Bayer Schering Pharma AG - SWOT Analysis
| Mar 2008 |
£63 |
Dyax Corp - SWOT Analysis
| Mar 2008 |
£63 |
Hillenbrand Industries, Inc. - SWOT Analysis
| Mar 2008 |
£63 |
Wyeth - SWOT Analysis
| Mar 2008 |
£63 |
Iasis Healthcare LLC - SWOT Analysis
| Mar 2008 |
£63 |
CollaGenex Pharmaceuticals, Inc. - SWOT Analysis
| Mar 2008 |
£63 |
Shionogi:
Pipeline Products Performance Potential
| Mar 2008 |
£595 |
Shionogi:
Pipeline Products Performance Potential
| Mar 2008 |
£595 |
Shionogi: Pipeline, Products, Performance, Potential
| Mar 2008 |
£595 |
Astellas: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
Allergan: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
Ono: Pipeline Products Performance Potential
| Feb 2008 |
£595 |
Bristol-Myers Squibb: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
Schering-Plough: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
Novartis: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
GlaxoSmithKline: Pipeline , Products , Performance , Potential
| Feb 2008 |
£595 |
Takeda Pipeline Products Performance Potential
| Feb 2008 |
£595 |
Gilead Sciences: Pipeline Products Performance Potential
| Feb 2008 |
£595 |
Merck KGaA - SWOT Analysis
| Feb 2008 |
£63 |
E.ON - SWOT Analysis
| Feb 2008 |
£63 |
Siemens Medical Solutions - SWOT Analysis
| Feb 2008 |
£63 |
Protherics PLC - SWOT Analysis
| Feb 2008 |
£63 |
CuraGen Corporation - SWOT Analysis
| Feb 2008 |
£63 |
Crucell N.V. - SWOT Analysis
| Feb 2008 |
£63 |
OPG Groep - SWOT Analysis
| Feb 2008 |
£63 |
Schwarz Pharma AG - SWOT Analysis
| Feb 2008 |
£63 |
previous
